Onvansertib

DB15110InvestigationalSmall molecule

Onvansertib is under investigation in clinical trial NCT03303339 (Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML).).

Mechanism: Pharmacologically active on Serine/threonine-protein kinase PLK1
Curator reviewed
Formula / weight: C₂₄H₂₇F₃N₈O₃ · 532.5182 g/mol (avg)
Also known as: 1-(2-Hydroxyethyl)-8-((5-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy)phenyl)amino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
Code names: NMS-1286937 · NMS-P937 · PCM-075

Resolves to

Compound

UNII67RM91WDHQCAS1034616-18-6ChEMBLCHEMBL1738758

Structure

InChIKeyQHLVBNKYJGBCQJ-UHFFFAOYSA-NSMILESCN1CCN(CC1)C1=CC(NC2=NC=C3CCC4=C(N(CCO)N=C4C(N)=O)C3=N2)=C(OC(F)(F)F)C=C1

Targets

P53350PLK1

What you can answer from here — as of July 17, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

14Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Onvansertib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account